Aberrant RNA Splicing Junctions Provide Promising T-cell Therapy Targets Available to Purchase

Major Finding: Aberrant RNA splicing leads to the tumor-wide expression of tumor-specific neojunctions that are presented and recognized by cytotoxic T cells.
Concept: Neojunctions can be expressed throughout the tumor and during progression, providing a potential neoantigen that overcomes the challenge of intratumoral heterogeneity.
Impact: This study highlights a promising source of public neoantigens that may be targeted for tumor-specific immunotherapy.